MANAGING PARKINSON'S DISEASE AT EVERY STAGE
Treatment of Parkinson's Disease with MIRAPEX
MIRAPEX is effective in both early and late stages of Parkinson's disease
MIRAPEX is a drug that is approved by the FDA for treating the signs and symptoms of Parkinson's disease.10 In a clinical study, patients recently diagnosed with Parkinson's disease had improvement in their activities of daily living.
MIRAPEX can be used alone, or in combination with other therapies, and is effective in treating both early and advanced stages of the disease.11,12
When used as initial therapy, it helps patients maintain their everyday activities.18 MIRAPEX may be used as a single therapy during the early stages of Parkinson's disease. In fact, after 4 years of pramipexole therapy in a clinical study, there was a 41% chance of remaining on MIRAPEX alone without the need to add levodopa.11 Levodopa may then be reserved, often for several years, until needed. (Levodopa therapy significantly improves symptoms for most patients. However, as the disease advances, the benefits of the drug last for shorter and shorter periods of time.27)
A levodopa-friendly therapy
MIRAPEX also may be used with levodopa therapy. This may allow patients to take a lower dose of levodopa. Using MIRAPEX in combination with levodopa therapy may help make the benefits of levodopa therapy last longer. Studies show that when MIRAPEX is added to levodopa therapy, patients have improved functioning. MIRAPEX increased the patients' daily "on" time, or time when symptoms are generally controlled, by as much as 2 hours.12,13
MIRAPEX has been shown to be very effective in improving tremor. A study showed that the majority of patients taking MIRAPEX saw an improvement in tremor symptoms.19
To find out if MIRAPEX is right for you or your loved one, talk with your doctor. Print this page and bring it to your next visit.
Patients and care partners should be informed that impulse control disorders/compulsive behaviors may occur while taking medicines, including MIRAPEX, to treat Parkinson's disease.
| KEY POINTS |
|---|
|
